Leavitt, A. D., Mahlangu, J., Raheja, P., Symington, E., Quon, D. V., Giermasz, A., . . . Ozelo, M. C. Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trial. Elsevier.
Chicago Style (17th ed.) CitationLeavitt, Andrew D., et al. Efficacy, Safety, and Quality of Life 4 Years After Valoctocogene Roxaparvovec Gene Transfer for Severe Hemophilia A in the Phase 3 GENEr8-1 Trial. Elsevier.
MLA (9th ed.) CitationLeavitt, Andrew D., et al. Efficacy, Safety, and Quality of Life 4 Years After Valoctocogene Roxaparvovec Gene Transfer for Severe Hemophilia A in the Phase 3 GENEr8-1 Trial. Elsevier.
Warning: These citations may not always be 100% accurate.